Dexcom INC

DexCom announced robust second quarter 2026 financial results, exceeding expectations with a 13% revenue increase and raising its full-year guidance.

DexCom shareholders successfully elected twelve directors, ratified its auditor, and approved executive compensation at the 2026 Annual Meeting.

Dexcom, Inc. announced Kevin R. Sayer's return from temporary leave to resume his role as Executive Chairman with a new compensation package.

Dexcom strengthens its board with the appointment of Google executive Rick Osterloh, bringing extensive tech and product leadership.

Dexcom reported strong fourth quarter and full year 2025 financial results, driven by significant revenue growth and strategic product launches, while reiterating robust 2026 guidance.

Dexcom reported preliminary unaudited Q4 and full-year 2025 revenue exceeding guidance, alongside a positive initial financial outlook for 2026 and a new CEO.

DexCom, Inc. announced its second quarter 2026 financial results, showcasing a 13% increase in revenue to $1.31 billion and a significant 50% rise in operating income.

DexCom reported strong Q1 2026 growth with $1.19 billion in revenue and a 91% increase in operating income compared to the prior year.

Dexcom reports strong third-quarter 2025 financial results with significant revenue and net income growth, alongside new product clearances and an ongoing share repurchase program.

Dexcom, a leader in continuous glucose monitoring systems, announced robust second-quarter financial results with significant revenue and net income growth, while addressing ongoing regulatory challenges and market pricing pressures.

Dexcom's Q1 2025 revenue increased by 12% year-over-year, while net income decreased due to higher income tax expenses.

Dexcom's third-quarter results show a slight revenue increase but a decrease in profitability, alongside ongoing legal challenges and strategic adjustments.

Dexcom, Inc. announced robust financial results for fiscal year 2025, driven by increased sales volume of its continuous glucose monitoring systems and the launch of new products like G7 15 Day and Stelo.

Dexcom's 2024 annual report reveals an 11% increase in revenue, reaching $4.03 billion, driven by growth in continuous glucose monitoring systems.

DexCom's recent SEC filing details the company's capital stock, governance, and anti-takeover provisions, providing investors with a comprehensive overview of its structure.

Mark G Foletta, a Director of Dexcom Inc, sold 4,000 shares of common stock on July 31, 2026.

Kevin R Sayer, Executive Chair and a Director of Dexcom Inc, sold 26,756 shares of common stock on July 20, 2026 for $76.32 per share.

Michael Jon Brown, EVP Chief Legal Compliance Off of Dexcom Inc, sold 1,700 shares of common stock on July 15, 2026 for $74.42 per share.

Dexcom Executive Chair Kevin R. Sayer sold 26,756 shares of common stock for $72 per share under a pre-arranged 10b5-1 trading plan.

DexCom Inc. reports that Michael Jon Brown, EVP Chief Legal Compliance Off, sold 1,700 shares of common stock on June 15, 2026, as part of a pre-arranged 10b5-1 trading plan.

DexCom Director Mark G. Foletta sold a total of 6,530 shares of common stock through his family trust, executing trades under a pre-arranged 10b5-1 plan.

DexCom, Inc. announced its 2026 Annual Meeting of Stockholders, highlighting robust 2025 financial and operational achievements, including significant revenue and income growth, new product launches, and expanded customer access.

DexCom announces the resignation of director Karen Dahut, effective May 8, 2025, just before the company's annual shareholder meeting.

DexCom, Inc. has filed a definitive proxy statement with the SEC.

DexCom is asking stockholders to approve amendments to its equity incentive and employee stock purchase plans to extend their terms and increase the number of shares available for issuance.

DexCom, Inc.'s proxy statement details the agenda for the 2024 annual stockholders meeting and reviews the company's strong 2023 financial results, including a 24% increase in revenue.

Vanguard Capital Management has filed a Schedule 13G reporting a 7.49% beneficial ownership stake in Dexcom Inc.

Vanguard Portfolio Management reports beneficial ownership of over 19.3 million shares, representing 5.02% of Dexcom Inc.'s common stock.

The Vanguard Group has reported a 0% beneficial ownership in Dexcom Inc. common stock following an internal realignment that disaggregated reporting responsibilities.

The Vanguard Group reported a significant beneficial ownership stake of 12.61% in Dexcom Inc., holding 49.46 million shares as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.3% of Dexcom Inc.'s common stock as of March 31, 2025.